Abstract
Purpose
To describe the imaging appearance of hyperenhancing nodules arising in post-Fontan patients and to identify specific features best correlated with malignancy.
Methods
Hyperenhancing hepatic nodules visible on CT and/or MRI in post-Fontan patients were identified retrospectively and reviewed by subspecialty radiologists. Nodules with characteristic imaging findings of focal nodular hyperplasia (FNH) were defined as typical, the remainder were defined as atypical, described in detail according to LIRADS criteria, and length of stability over time was recorded. Clinical data, alpha fetoprotein levels (AFP), central venous pressures (CVP), and histopathology were recorded.
Results
245 hyperenhancing nodules (215 typical, 30 atypical) were evaluated in 30 patients. Twenty-nine atypical nodules showed washout (portal phase in 6, delayed phase in 29), 0 showed pseudocapsule, 1 showed threshold growth, 1 showed tumor in vein, and 5 showed ancillary features favoring malignancy. Pathology confirmed hepatocellular carcinoma (HCC) in 3 atypical nodules and FNH-like histology in 3 atypical and 4 typical nodules. 2 atypical nodules were present in a patient with clinical diagnosis of HCC. 20 nodules (7 typical, 13 atypical due to washout) were studied with hepatobiliary contrast agent and all showed homogenous hepatobiliary phase retention. Atypical nodules were significantly more likely to be HCC than biopsy-proven FNH-like or stable ≥24 months when showing portal phase washout (P < 0.001), mosaic architecture (P = 0.020) or in the presence of cirrhosis (P = 0.004) or elevated AFP (P = 0.004). Atypical nodules that were HCC had higher median CVP than those that were FNH-like (19, range 16–27 vs. 13, range 12–16 mmHg, P = 0.0003), there was not a significant difference based on median patient age (HCC 30, range 10–41 vs. FNH-like 40 range 10–41, P = 0.244).
Conclusions
Benign hyperenhancing masses in Fontan patients may demonstrate washout and be mistaken for HCC by imaging criteria. Portal phase washout, mosaic architecture, elevated AFP and higher CVP were associated with HCC in the atypical nodules found in this population.
Similar content being viewed by others
References
Asrani SK, Asrani NS, Freese DK, et al. (2012) Congenital heart disease and the liver. Hepatology 56(3):1160–1169. doi:10.1002/hep.25692
Rychik J, Veldtman G, Rand E, et al. (2012) The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol 33(7):1001–1012. doi:10.1007/s00246-012-0315-7
Bryant T, Ahmad Z, Millward-Sadler H, et al. (2011) Arterialised hepatic nodules in the Fontan circulation: hepatico-cardiac interactions. Int J Cardiol 151(3):268–272. doi:10.1016/j.ijcard.2010.05.047
Kendall TJ, Stedman B, Hacking N, et al. (2008) Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study. J Clin Pathol 61(4):504–508. doi:10.1136/jcp.2007.052365
Dai DF, Swanson PE, Krieger EV, et al. (2014) Congestive hepatic fibrosis score: a novel histologic assessment of clinical severity. Mod Pathol 27(12):1552–1558. doi:10.1038/modpathol.2014.79
Bulut OP, Romero R, Mahle WT, et al. (2013) Magnetic resonance imaging identifies unsuspected liver abnormalities in patients after the Fontan procedure. J Pediatr 163(1):201–206. doi:10.1016/j.jpeds.2012.12.071
Kiesewetter CH, Sheron N, Vettukattill JJ, et al. (2007) Hepatic changes in the failing Fontan circulation. Heart 93(5):579–584. doi:10.1136/hrt.2006.094516
Wallihan DB, Podberesky DJ (2013) Hepatic pathology after Fontan palliation: spectrum of imaging findings. Pediatr Radiol 43(3):330–338. doi:10.1007/s00247-012-2531-y
Asrani SK, Warnes CA, Kamath PS (2013) Hepatocellular carcinoma after the Fontan procedure. N Engl J Med 368(18):1756–1757. doi:10.1056/NEJMc1214222
Ewe SHT, Ju L (2009) Hepatotocellular carcinoma—a rare complication post Fontan operation. Congenit Heart Dis 4(2):103–106. doi:10.1111/j.1747-0803.2009.00255.x
Ghaferi AA, Hutchins GM (2005) Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg 129(6):1348–1352. doi:10.1016/j.jtcvs.2004.10.005
Rajoriya N, Clift P, Thorne S, Hirschfield GM, Ferguson JW (2014) A liver mass post-Fontan operation. QJM 107(7):571–572. doi:10.1093/qjmed/hcu020
Rosenbaum J, Vrazas J, Lane GK, Hardikar W (2012) Cardiac cirrhosis and hepatocellular carcinoma in a 13-year-old treated with doxorubicin microbead transarterial chemoembolization. J Paediatr Child Health 48(3):E140–E143. doi:10.1111/j.1440-1754.2010.01932.x
Saliba T, Dorkhom S, O’Reilly EM, et al. (2010) Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol 22(7):889–891. doi:10.1097/MEG.0b013e32832e2bec
Wanless IR (1995) Terminology of nodular hepatocellular lesions. Hepatology 22(3):983–993
Josephus Jitta D, Wagenaar LJ, Mulder BJ, et al. (2016) Three cases of hepatocellular carcinoma in Fontan patients: review of the literature and suggestions for hepatic screening. Int J Cardiol 206:21–26. doi:10.1016/j.ijcard.2015.12.033
Yamada K, Shinmoto H, Kawamura Y, et al. (2015) Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis. Pediatr Int 57(4):766–770. doi:10.1111/ped.12619
Elder RW, Parekh S, Book WM (2013) More on hepatocellular carcinoma after the Fontan procedure. N Engl J Med 369(5):490. doi:10.1056/NEJMc1306854
Wells ML, Fenstad ER, Poterucha JT, et al. (2016) Imaging findings of congestive hepatopathy. Radiographics 36(4):1024–1037. doi:10.1148/rg.2016150207
Choi JY, Lee HC, Yim JH, et al. (2011) Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis. J Gastroenterol Hepatol 26(6):1004–1009. doi:10.1111/j.1440-1746.2011.06659.x
Lee YH, Kim SH, Cho MY, Shim KY, Kim MS (2007) Focal nodular hyperplasia-like nodules in alcoholic liver cirrhosis: radiologic-pathologic correlation. AJR Am J Roentgenol 188(5):W459–W463. doi:10.2214/AJR.05.1998
Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022. doi:10.1002/hep.24199
Libbrecht L, Cassiman D, Verslype C, et al. (2006) Clinicopathological features of focal nodular hyperplasia-like nodules in 130 cirrhotic explant livers. Am J Gastroenterol 101(10):2341–2346. doi:10.1111/j.1572-0241.2006.00783.x
European Association For The Study Of The L, European Organisation For R, Treatment Of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943. doi:10.1016/j.jhep.2011.12.001
Trevisani F, D’Intino PE, Morselli-Labate AM, et al. (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34(4):570–575
Kubota K, Ina H, Okada Y, Irie T (2003) Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci 48(3):581–586
Taouli B, Goh JS, Lu Y, et al. (2005) Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr 29(4):425–429
Furlan A, Marin D, Agnello F, et al. (2012) Hepatocellular carcinoma presenting at contrast-enhanced multi-detector-row computed tomography or gadolinium-enhanced magnetic resonance imaging as a small (≤2 cm), indeterminate nodule: growth rate and optimal interval time for imaging follow-up. J Comput Assist Tomogr 36(1):20–25. doi:10.1097/RCT.0b013e31823ed462
Varenika V, Fu Y, Maher JJ, et al. (2013) Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT. Radiology 266(1):151–158. doi:10.1148/radiol.12112452
Zissen MH, Wang ZJ, Yee J, et al. (2013) Contrast-enhanced CT quantification of the hepatic fractional extracellular space: correlation with diffuse liver disease severity. AJR Am J Roentgenol 201(6):1204–1210. doi:10.2214/AJR.12.10039
Bandula S, Punwani S, Rosenberg WM, et al. (2015) Equilibrium contrast-enhanced CT imaging to evaluate hepatic fibrosis: initial validation by comparison with histopathologic sampling. Radiology 275(1):136–143. doi:10.1148/radiol.14141435
Wells ML, Fenstad ER, Poterucha JT, et al. (2016) Imaging findings of congestive hepatopathy. Radiographics. doi:10.1148/rg.2016150207
European Association For The Study Of The Liver (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943. doi:10.1016/j.jhep.2011.12.00
Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 273(1):30–50. doi:10.1148/radiol.14132362
Hope TA, Fowler KJ, Sirlin CB, et al. (2015) Hepatobiliary agents and their role in LI-RADS. Abdom Imaging 40(3):613–625. doi:10.1007/s00261-014-0227-5
Suh YJ, Kim MJ, Choi JY, et al. (2011) Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. AJR Am J Roentgenol 197(1):W44–W52. doi:10.2214/AJR.10.5845
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding was received for this study.
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Rights and permissions
About this article
Cite this article
Wells, M.L., Hough, D.M., Fidler, J.L. et al. Benign nodules in post-Fontan livers can show imaging features considered diagnostic for hepatocellular carcinoma. Abdom Radiol 42, 2623–2631 (2017). https://doi.org/10.1007/s00261-017-1181-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-017-1181-9